Table of Contents
What changed
Reported revenue fell 29.5% to $250.2m from $355.1m, with the Community Health segment (prior-period revenue $106.5m, prior result $6.6m) no longer reported in HY24. PBT halved to $10.5m from $21.3m (-50.5%) and parent NPAT fell to $5.6m from $11.4m (-50.6%). Operating cash flow dropped to $18.8m from $28.9m (-35.0%). The balance sheet deteriorated materially: cash fell to $18.5m from $43.6m, gross borrowings rose 26.7% to $31.4m, and a prior $18.9m net cash position became $12.9m of net debt. Within the continuing mix, Pharmacy revenue was broadly flat at $181.5m (vs $179.5m) but its segment result fell to $8.7m from $11.6m; Medical revenue was flat at $68.6m with result down to $7.3m from $9.3m.
What matters
- Underlying margin compression, not just the segment exit. Stripping out Community Health, the two remaining segments were revenue-flat but earnings weaker: Pharmacy margin fell to ~4.8% from ~6.5%, Medical to ~10.7% from ~13.6%. The 50% PBT decline is therefore not fully explained by the disappearance of Community Health.
- Leverage direction has reversed. Moving from $18.9m net cash to $12.9m net debt inside twelve months, with cash down $25.2m, is the single biggest balance-sheet signal and tightens the margin for error on dividend and capex policy going forward.
- ROE has weakened sharply to 3.4% from 6.5%, reflecting lower earnings on a smaller equity base ($162.6m vs $174.9m).
Expectations
No forward guidance, target, or forward-work disclosure was supplied. On seasonality, the prior-year shape is not a clean guide: HY23 represented 71.9% of FY23 revenue (distorted by the now-absent Community Health) and only 25.1% of FY23 NPAT, where the full-year bottom line was boosted by a discontinued-operation gain. Annualised HY24 revenue of ~$500.4m is roughly in line with FY23's $493.6m, but the FY23 NPAT of $45.2m is not a meaningful reference point for the continuing business. This release does not support any specific FY24 earnings shape claim.
Quality of result
Cash conversion itself did not deteriorate on a relative basis — pre-lease free cash flow of $15.6m comfortably covered NPAT, and OCF fell less than proportionately to earnings. Receivable days improved to 12.9 from 17.2, which flattered the cash number; inventory days rose to 23.8 from 16.6, a partial offset. The effective tax rate eased to 27.1% from 30.3%, modestly flattering NPAT versus PBT, but not enough to call the tax line distortive. The more important quality question is margin: with continuing-segment revenue flat and both segment margins down 150–300bps, the earnings decline looks operational rather than one-off or timing-driven.
Unresolved
- What drove the fall in Pharmacy and Medical segment margins on essentially flat revenue — cost inflation, mix within each segment, or one-offs?
- What happened to Community Health: was it divested, deconsolidated, or reclassified, and are there residual cash or balance-sheet effects still flowing through?
- What explains the $25.2m cash drawdown alongside higher borrowings — acquisitions, dividends, working-capital timing, or deconsolidation effects?
- No EBITDA, net-debt-to-earnings ratio, dividend details, or forward-work figures were provided, and no NTA or share price was supplied, so this briefing cannot assess leverage multiples, payout sustainability, valuation, or management's own characterisation of the Community Health change.
Key metrics
| Metric | HY24 | HY23 | Change |
|---|---|---|---|
| Revenue | $250.2m | $355.1m | -29.5% ↓ |
| Net profit after tax | $5.6m | $11.4m | -50.6% ↓ |
| Net cash inflow from operating activities | $18.8m | $28.9m | -35.0% ↓ |
| Operating profit | $14.9m | $24.7m | -39.5% ↓ |
| Profit before tax | $10.5m | $21.3m | -50.5% ↓ |
| Cash and cash equivalents | $18.4m | $43.6m | -57.7% ↓ |
| Total assets | $374.9m | $414.5m | -9.5% ↓ |
Reference: annolyse.ai/briefings/gxh-hy24
Segment breakdown
| Segment | Current revenue | Prior revenue | Current result | Mix shift |
|---|---|---|---|---|
| Pharmacy services | $181.5m | $179.5m | $8.7m | +22.1pp |
| Medical services | $68.6m | $68.2m | $7.3m | +8.2pp |
| Community Health | — | $106.5m | — | n/a |
Reference: annolyse.ai/briefings/gxh-hy24
Analytical metrics
| Metric | HY24 | HY23 | Context |
|---|---|---|---|
| PBT growth | -50.5% | — | — |
| Effective tax rate | 27.1% | 30.3% | — |
| FCF pre-lease | $15.6m | $25.8m | −$10.3m |
| FCF / NPAT | 277.7% | 227.5% | complementary conversion metric |
| Capex % revenue | 1.3% | 0.9% | — |
| Capex | −$3.2m | −$3.0m | −$0.2m |
| Debtor days | 12.9 | 17.2 | -4.3 days |
| Inventory days | 23.8 | 16.6 | +7.2 days |
| Trade debtors | $17.7m | $33.6m | −$15.9m |
| Net debt | $12.9m | −$18.9m | +$31.8m |
| Gross borrowings | $31.4m | $24.8m | +$6.6m |
| ROE (annualised) | 3.4% | 6.5% | Weakening |
| HY23 share of FY23 revenue | 71.9% | — | Other half was 28.1% |
| HY23 share of FY23 NPAT | 25.1% | — | Other half was 74.9% |
| Profit from continuing operations | $7.7m | — | — |
Reference: annolyse.ai/briefings/gxh-hy24
This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.